Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.
Syros Receives FDA Orphan Drug Designation For SY-5609 For The Treatment Of Pancreatic Cancer
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
Gainers
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average price of $2.03 - $2.07.
FDA Grants Syros Pharmaceuticals Orphan Drug Designation For Treatment Of Pancreatic Cancer – FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=898122
What 4 Analyst Ratings Have To Say About Syros Pharmaceuticals
Analysts have provided the following ratings for Syros Pharmaceuticals (NASDAQ:SYRS) within the last quarter: